Brief: Kabouter Management Buys H-Shares In Haohai Biological Technology - HKEX Filing
Oct 19 (Reuters) - Hong Kong stock exchange filing:
* KABOUTER MANAGEMENT LLC BOUGHT 273,800 H-SHARES IN
SHANGHAI
HAOHAI BIOLOGICAL TECHNOLOGY 6826.HK AT AVG PRICE OF HK$65.45
($8.41) PER SHARE ON OCT 18 - HKEX FILING
* KABOUTER MANAGEMENT LLC'S LONG POSITION IN SHANGHAI HAOHAI
BIOLOGICAL TECHNOLOGY RISES TO 9.27% FROM 8.55% - HKEX FILING
Source text https://di.hkex.com.hk/di/NSForm2.aspx?fn=CS20211019E00013&sa2=ns&sid=119410&sd=19/10/2020&ed=19/10/2021&sa1=cl&scsd=19/10/2020&sced=19/10/2021&sc=06826&src=Main&lang=EN&tk=ds
Further company coverage: 6826.HK
($1 = 7.7779 Hong Kong dollars)
(Reporting by Hong Kong newsroom)
((twinnie.siu@tr.com; 852-3462 7715;))
Recent news on Shanghai Haohai Biological Technology
See all newsChina's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distribution
Brief: Shanghai Haohai Biological Technology Says Resignation Of Hou Yongtai As Exec Director, Chair
Brief: Shanghai Haohai Biological Technology Updates On Investigation Of Jiang Wei's Suspected Insider Trading Case
Brief: Shanghai Haohai Biological Technology Proposes To Elect Tian Min As An Additional Executive Director
Brief: Shanghai Haohai Biological Technology Posts Qtrly Net profit Attributable Of RMB73.6 Mln.